VYNE Therapeutics Inc. filed its 10-K on Mar 14, 2023 for the period ending Dec 31, 2022. In this report its auditor, Baker Tilly, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.7 USD | -2.17% | +1.89% | +15.88% |
05-09 | Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q1 Revenue $98,000 | MT |
05-09 | VYNE Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.88% | 38.07M | |
+32.36% | 694B | |
+30.07% | 593B | |
-1.60% | 371B | |
+20.07% | 331B | |
+6.04% | 290B | |
+14.42% | 239B | |
+10.27% | 209B | |
-3.19% | 209B | |
+9.27% | 169B |
- Stock Market
- Equities
- VYNE Stock
- News VYNE Therapeutics Inc.
- VYNE Therapeutics Inc. Auditor Raises 'Going Concern' Doubt